section name header

Pronunciation ⬇

ole-me-SAR-tan me-DOX-o-mil

Classifications ⬆ ⬇

Therapeutic Classification: antihypertensives

Pharmacologic Classification: angiotensin II receptor antagonists

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

  • Blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II at various receptor sites including vascular smooth muscle and the adrenal glands.
Therapeutic effects:
  • Reduction of BP.

Pharmacokinetics ⬆ ⬇

Absorption: Olmesartan medoxomil is a prodrug that is converted to olmesartan (the active component); 26% bioavailability of olmesartan.

Distribution: Crosses the placenta.

Protein Binding: 99%.

Metabolism/Excretion: No further metabolism following conversion of prodrug to active drug; 35–50% excreted unchanged in urine; remainder eliminated in feces via bile.

Half-Life: 13 hr.

Time/Action Profile ⬆ ⬇

(antihypertensive effect with chronic dosing)

ROUTEONSETPEAKDURATION
POwithin 1 wk2 wk24 hr



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: hypotension

F and E: hyperkalemia

GI: sprue-like enteropathy

GU: impaired renal function

Neuro: dizziness

Misc: ANGIOEDEMA

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Benicar

Canadian Brand Names ⬆ ⬇

Olmetec

Pill Image

olmesartanmedoxomil_195-8697.jpg
olmesartan_medoxomil-hcl_195-8688.jpg

Code ⬆

NDC Code